A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date

References

• Centers for Disease Control and Prevention (U.S.). Antibiotic Resistance Threats in the United States, 2019. Centers for Disease Control and Prevention (U.S.); 2019.
   Google Scholar
• Bogan C, Kaye KS, Chopra T, et al. Outcomes of carbapenem-resistant Enterobacteriaceae isolation: matched analysis. Am J Infect Control. 2014;42(6):612–620. doi:10.1016/j.ajic.2014.02.01324837111
   PubMed Web of Science ®Google Scholar
• Martin A, Fahrbach K, Zhao Q, Lodise T. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: results of a systematic literature review and meta-analysis. Open Forum Infect Dis. 2018;5(7). doi:10.1093/ofid/ofy150
   Web of Science ®Google Scholar
• Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027–1052. doi:10.2165/00003495-200767070-0000617488146
   PubMed Web of Science ®Google Scholar
• Hirsch EB, Ledesma KR, Chang K-T, Schwartz MS, Motyl MR, Tam VH. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant gram-negative bacteria. Antimicrob Agents Chemother. 2012;56(7):3753–3757. doi:10.1128/AAC.05927-1122526311
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem-relebactam against clinical isolates of gram-negative bacilli isolated in hospital laboratories in the United States as part of the SMART 2016 program. Antimicrob Agents Chemother. 2018;62(7). doi:10.1128/AAC.00169-18
   Web of Science ®Google Scholar
• Karlowsky JA, Lob SH, Kazmierczak KM, et al. In vitro activity of imipenem/relebactam against gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme. J Antimicrob Chemother. 2018;73(7):1872–1879. doi:10.1093/jac/dky10729659861
   PubMed Web of Science ®Google Scholar
• Lob SH, Hackel MA, Kazmierczak KM, et al. In vitro activity of imipenem-relebactam against gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (Results from the SMART global surveillance program). Antimicrob Agents Chemother. 2017;61(6). doi:10.1128/AAC.02209-16
   Web of Science ®Google Scholar
• Bush K. Past and present perspectives on β-lactamases. Antimicrob Agents Chemother. 2018;62(10):e01076. doi:10.1128/AAC.01076-1830061284
   PubMed Web of Science ®Google Scholar
• Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995;39(6):1211–1233. doi:10.1128/AAC.39.6.12117574506
   PubMed Web of Science ®Google Scholar
• Crass RL, Pai MP. Pharmacokinetics and pharmacodynamics of β-lactamase inhibitors. Pharmacotherapy. 2019;39(2):182–195. doi:10.1002/phar.221030589457
   PubMed Web of Science ®Google Scholar
• McLeod DC, Lyon JA. Imipenem/cilastatin: the first carbapenem antibiotic. Drug Intell Clin Pharm. 1985;19(12):894–899. doi:10.1177/106002808501901202
   Google Scholar
• Recarbrio (imipenem/cilastatin/relebactam) [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 7 2019.
   Google Scholar
• Zhanel GG, Simor AE, Vercaigne L, Mandell L. Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can J Infect Dis. 1998;9(4):215–228.22346545
   PubMedGoogle Scholar
• Tooke CL, Hinchliffe P, Lang PA, et al. Molecular basis of class A β-lactamase inhibition by relebactam. Antimicrob Agents Chemother. 2019;63(10):e00564. doi:10.1128/AAC.00564-1931383664
   PubMed Web of Science ®Google Scholar
• Papp-Wallace KM, Barnes MD, Alsop J, et al. Relebactam is a potent inhibitor of the KPC-2 β-lactamase and restores imipenem susceptibility in KPC-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62(6). doi:10.1128/AAC.00174-18
   Web of Science ®Google Scholar
• Lob SH, Karlowsky JA, Young K, et al. In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART surveillance Europe 2015–2017. J Med Microbiol. 2020;69(2):207–217. doi:10.1099/jmm.0.00114231976856
   PubMed Web of Science ®Google Scholar
• El Hafi B, Rasheed SS, Abou Fayad AG, Araj GF, Matar GM. Evaluating the efficacies of carbapenem/β-lactamase inhibitors against carbapenem-resistant gram-negative bacteria in vitro and in vivo. Front Microbiol. 2019;10. doi:10.3389/fmicb.2019.00933.
   Web of Science ®Google Scholar
• Gomez-Simmonds A, Stump S, Giddins MJ, Annavajhala MK, Uhlemann A-C. Clonal background, resistance gene profile, and porin gene mutations modulate in vitro susceptibility to imipenem-relebactam in diverse Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62(8). doi:10.1128/AAC.00573-18
   Web of Science ®Google Scholar
• Haidar G, Clancy CJ, Chen L, et al. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(9). doi:10.1128/AAC.00642-17
   Web of Science ®Google Scholar
• Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of imipenem with relebactam against gram-negative pathogens from New York City. Antimicrob Agents Chemother. 2015;59(8):5029–5031. doi:10.1128/AAC.00830-1526014931
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;dkt178. doi:10.1093/jac/dkt178
   Web of Science ®Google Scholar
• Schmidt-Malan SM, Mishra AJ, Mushtaq A, Brinkman CL, Patel R. In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli. Antimicrob Agents Chemother. 2018;62(8). doi:10.1128/AAC.00533-18
   Web of Science ®Google Scholar
• Biagi M, Shajee A, Vialichka A, Jurkovic M, Tan X, Wenzler E. Activity of imipenem-relebactam and meropenem-vaborbactam against carbapenem-resistant, SME-producing serratia marcescens. Antimicrob Agents Chemother. 2020;64(4). doi:10.1128/AAC.02255-19
   Web of Science ®Google Scholar
• Johnston BD, Thuras P, Porter SB, et al. Activity of imipenem/relebactam against carbapenem-resistant Escherichia coli isolates from the United States in relation to clonal background, resistance genes, co-resistance, and region. Antimicrob Agents Chemother. 2020. doi:10.1128/AAC.02408-19
   Web of Science ®Google Scholar
• Kulengowski B, Burgess DS. Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center. Pathog Dis. 2019;77(4):ftz040. doi:10.1093/femspd/ftz04031365075
   PubMed Web of Science ®Google Scholar
• Carpenter J, Neidig N, Campbell A, et al. Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance. J Antimicrob Chemother. 2019;74(11):3260–3263. doi:10.1093/jac/dkz35431430370
   PubMed Web of Science ®Google Scholar
• Balabanian G, Rose M, Manning N, Landman D, Quale J. Effect of porins and blaKPC expression on activity of imipenem with relebactam in Klebsiella pneumoniae: can antibiotic combinations overcome resistance? Microb Drug Resist. 2018;24(7):877–881. doi:10.1089/mdr.2018.006529782237
   PubMed Web of Science ®Google Scholar
• Senchyna F, Gaur RL, Sandlund J, et al. Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016. Diagn Microbiol Infect Dis. 2019;93(3):250–257. doi:10.1016/j.diagmicrobio.2018.10.00430482638
   PubMed Web of Science ®Google Scholar
• Kahlmeter G, Giske CG, Kirn TJ, Sharp SE. Point-counterpoint: differences between the European committee on antimicrobial susceptibility testing and clinical and laboratory standards institute recommendations for reporting antimicrobial susceptibility results. Caliendo AM ed. J Clin Microbiol. 2019;57(9):e01129. doi:10.1128/JCM.01129-1931315957
   PubMed Web of Science ®Google Scholar
• Canver MC, Satlin MJ, Westblade LF, et al. Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019;63(9). doi:10.1128/AAC.00672-19
   Web of Science ®Google Scholar
• Galani I, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, Antoniadou A. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015–2016. Eur J Clin Microbiol Infect Dis. 2019;38(6):1143–1150. doi:10.1007/s10096-019-03517-y30825054
   PubMed Web of Science ®Google Scholar
• Barnes MD, Bethel CR, Alsop J, et al. Inactivation of the pseudomonas-derived cephalosporinase-3 (PDC-3) by relebactam. Antimicrob Agents Chemother. 2018;62(5):e02406–17. doi:10.1128/AAC.02406-1729530851
   PubMed Web of Science ®Google Scholar
• Horner C, Mushtaq S, Livermore DM, et al. Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections. J Antimicrob Chemother. 2019;74(7):1940–1944. doi:10.1093/jac/dkz13331032858
   PubMed Web of Science ®Google Scholar
• Asempa TE, Nicolau DP, Kuti JL. In vitro activity of imipenem-relebactam alone or in combination with amikacin or colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63(9). doi:10.1128/AAC.00997-19
   Web of Science ®Google Scholar
• Asempa TE, Nicolau DP, Kuti JL. Carbapenem-nonsusceptible Pseudomonas aeruginosa isolates from intensive care units in the United States: a potential role for new β-lactam combination agents. J Clin Microbiol. 2019;57(8). doi:10.1128/JCM.00535-19
   Web of Science ®Google Scholar
• Fraile-Ribot PA, Zamorano L, Orellana R, et al. Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic β-lactam-resistant mutants. Antimicrob Agents Chemother. 2020;64(2). doi:10.1128/AAC.02165-19
   Web of Science ®Google Scholar
• Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. CMR. 2010;23(1):160–201. doi:10.1128/CMR.00037-09
   Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA. In vitro evaluation of the activity of imipenem-relebactam against 451 recent clinical isolates of bacteroides group and related species. Antimicrob Agents Chemother. 2016;60(10):6393–6397. doi:10.1128/AAC.01125-1627480858
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Citron DM, Tyrrell KL, Leoncio E, Merriam CV. Comparative in vitro activities of relebactam, imipenem, the combination of the two, and six comparator antimicrobial agents against 432 strains of anaerobic organisms, including imipenem-resistant strains. Antimicrob Agents Chemother. 2018;62(2). doi:10.1128/AAC.01992-17
   Web of Science ®Google Scholar
• Rhee EG, Rizk ML, Calder N, et al. Pharmacokinetics, safety, and tolerability of single and multiple doses of relebactam, a-lactamase inhibitor, in combination with imipenem and cilastatin in healthy participants. Antimicrob Agents Chemother. 2018;62(9):16.
   Web of Science ®Google Scholar
• Rizk ML, Rhee EG, Jumes PA, et al. Intrapulmonary pharmacokinetics of relebactam, a novel β-lactamase inhibitor, dosed in combination with imipenem-cilastatin in healthy subjects. Antimicrob Agents Chemother. 2018;62(3). doi:10.1128/AAC.01411-17
   Web of Science ®Google Scholar
• Bhagunde P, Patel P, Lala M, et al. Population pharmacokinetic analysis for imipenem–relebactam in healthy volunteers and patients with bacterial infections. CPT Pharmacometrics Syst Pharmacol. 2019;8(10):748–758. doi:10.1002/psp4.1246231508899
   PubMedGoogle Scholar
• Chan G, Houle R, Lin M, et al. Role of transporters in the disposition of a novel β-lactamase inhibitor: relebactam (MK-7655). J Antimicrob Chemother. 2019;74(7):1894–1903. doi:10.1093/jac/dkz10130891606
   PubMed Web of Science ®Google Scholar
• Lucasti C, Vasile L, Sandesc D, et al. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2016;60(10):6234–6243. doi:10.1128/AAC.00633-1627503659
   PubMed Web of Science ®Google Scholar
• Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017;72(9):2616–2626. doi:10.1093/jac/dkx13928575389
   PubMed Web of Science ®Google Scholar
• Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2019. doi:10.1093/cid/ciz530
   PubMed Web of Science ®Google Scholar
• Roquilly A, Titov I, Rodriguez Gonzalez D, et al. Outcomes in ventilated patients with hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) treated with imipenem/cilastatin/relebactam vs piperacillin/tazobactam: subgroup analysis of the RESTORE-IMI 2 randomized, controlled trial. Poster presented at the: ECCMID; 4 2020; Paris, France.
   Google Scholar
• Titov I, Wunderink R, Roquilly A, et al. RESTORE-IMI 2: randomized, double-blind, phase 3 trial comparing efficacy and safety of imipenem/cilastatin/relebactam vs piperacillin/tazobactam in adult patients with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP). Poster presented at the: ECCMID; 4 2020; Paris, France.
   Google Scholar
• Mori H, Takahashi K, Mizutani T. Interaction between valproic acid and carbapenem antibiotics. Drug Metab Rev. 2007;39(4):647–657. doi:10.1080/0360253070169034118058328
   PubMed Web of Science ®Google Scholar
• Gallagher JC, Satlin MJ, Elabor A, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study. Open Forum Infect Dis. 2018;5(11):ofy280. doi:10.1093/ofid/ofy28030488041
   PubMed Web of Science ®Google Scholar
• Tamma PD, Beisken S, Bergman Y, et al. Modifiable risk factors for the emergence of ceftolozane-tazobactam resistance. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa1306
   Web of Science ®Google Scholar
• Zhanel GG, Lawrence CK, Adam H, et al. Imipenem–relebactam and meropenem–vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations. Drugs. 2018;78(1):65–98. doi:10.1007/s40265-017-0851-929230684
   PubMed Web of Science ®Google Scholar
• Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against gram-negative clinical isolates in New York City. Antimicrob Agents Chemother. 2015;59(8):4856–4860. doi:10.1128/AAC.00843-1526033723
   PubMed Web of Science ®Google Scholar
• Shields RK, Doi Y. Aztreonam combination therapy: an answer to metallo-β-lactamase–producing gram-negative bacteria? Clin Infect Dis. 2019;ciz1159. doi:10.1093/cid/ciz1159
   Web of Science ®Google Scholar
• Shaw E, Rombauts A, Tubau F, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother. 2018;73(4):1104–1106. doi:10.1093/jac/dkx49629272413
   PubMed Web of Science ®Google Scholar
• Marshall S, Hujer AM, Rojas LJ, et al. Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017;61(4):e02243–16. doi:10.1128/AAC.02243-1628167541
   PubMed Web of Science ®Google Scholar
• Vabomere (meropenem and vaborbactam) [package insert]. Lincolnshire, IL: Melinta Therapeutics Inc; 2017.
   Google Scholar
• Vena A, Castaldo N, Bassetti M. The role of new β-lactamase inhibitors in gram-negative infections. Curr Opin Infect Dis. 2019;32(6):638–646. doi:10.1097/QCO.000000000000060031577557
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao C, Wang Q, et al. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR gram-negative bacterial isolates from China. J Antimicrob Chemother. 2020. doi:10.1093/jac/dkaa053
   Web of Science ®Google Scholar
• Hamrick JC, Docquier J-D, Uehara T, et al. VNRX-5133 (taniborbactam), a broad-spectrum inhibitor of serine- and metallo-β-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2020;64(3). doi:10.1128/AAC.01963-19
   Web of Science ®Google Scholar
• Tselepis L, Langley GW, Aboklaish AF, et al. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae. Int J Antimicrob Agents. 2020;56(1):105925. doi:10.1016/j.ijantimicag.2020.10592532084512
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Nelson K, Rubio-Aparicio D, Tsivkovski R, Sun D, Dudley MN. Impact of intrinsic resistance mechanisms on potency of QPX7728, a new ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases in Enterobacteriaceae, pseudomonas aeruginosa, and acinetobacter baumannii. Antimicrob Agents Chemother. 2020;64(6). doi:10.1128/AAC.00552-20
   Web of Science ®Google Scholar
• Tsivkovski R, Totrov M, Lomovskaya O. Biochemical characterization of QPX7728, a new ultra-broad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases. Antimicrob Agents Chemother. 2020;64(6). doi:10.1128/AAC.00130-20
   Web of Science ®Google Scholar